Loading...

LXEO LEXEO THERAPEUTICS INC Product Launches 8-K Filing

LX T

LX

LEXEO THERAPEUTICS INC

(LXEO)

2024 8-K

Financial Results Update

Director Appointment

Business Highlights

Management Change

Management Changes

Positive Clinical Data

Financial Results Announced

Funding Announcements

Regulatory Update

CFO Transition Announcement

Equity Offerings

Financial Statements

Clinical Data Announcement

Financial Results

Corporate Presentation

CFO Appointment

Management Change

Clinical Data Release

Corporate Update

External Links:

LEXEO Therapeutics announced positive interim Phase 1/2 clinical data for LX1001, a treatment for APOE4-associated Alzheimer's disease, and will host a conference call to discuss the findings.

AI Assistant

LEXEO THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.